Loading
A phase 2 trial of ivonescimab, fluorouracil and liposomal irinotecan in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies is a phase 2 interventional study registered as NCT06993025 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 30 participants, started 2025-05-25 and due to reach its primary completion in 2026-04-25. Interventions recorded: Ivonescimab+chemotherapy. Conditions listed: Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.
Shares Liposomal irinotecan, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
Shares Ivonescimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bispecific antibodies, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
Shares Liposomal irinotecan, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bispecific antibodies, Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Fluorouracil (5-FU), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Liposomal irinotecan, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
Shares Liposomal irinotecan, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bispecific antibodies, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.